Press releases

YearType

2023

1 Sep 2023, 12:00 | Regulatory

Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma

31 Jul 2023, 08:00 | Regulatory

Hansa Biopharma: Increase of the number of votes

20 Jul 2023, 07:00 | Regulatory

Hansa Biopharma half year report 2023

· Solid product sales in Q2 2023
· Collaboration announced in gene therapy with Genethon in Crigler-Najjar syndrome
· New Eurotransplant desensitization program implemented in June
· First patient treated in new investigator-initiated Phase 2 study in ANCA-associated vasculitis

19 Jul 2023, 08:00

First patient treated with imlifidase in an investigator-initiated Phase 2 study in ANCA-associated vasculitis

11 Jul 2023, 12:00 | Regulatory

Idefirix (imlifidase) receives provisional approval in Australia as desensitization treatment in highly sensitized patients prior to kidney transplantation

Regulatory milestone marks the first time Idefirix has been approved in kidney transplantation from both living and deceased donors

6 Jul 2023, 08:00

Hansa Biopharma to host conference call to provide half year results for January-June 2023 and a Business Update

4 Jul 2023, 12:05 | Regulatory

Hansa Biopharma AB recognizes a write-up of SEK 1.430 billion in intangible assets related to Idefirix in the financial statements of the parent company - no impact on the consolidated financials

29 Jun 2023, 17:00 | Regulatory

Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)